Dld Asset Management, LP Akebia Therapeutics, Inc. Transaction History

Dld Asset Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.32 - $0.67 $31,232 - $65,392	-97,600 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.72 - $2.93 $70,272 - $285,968	97,600 New	97,600 $70,000
Q4 2018 Feb 13, 2019	SELL	$5.39 - $9.15 $53,900 - $91,500	-10,000 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$7.44 - $10.65 $148,800 - $213,000	-20,000 Reduced 66.67%	10,000 $88,000
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $274,500 - $340,200	30,000 New	30,000 $299,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $346M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Dld Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Dld Asset Management, LP with notifications on news.